Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: The article did not discuss costs. Screening mammograms impose a significant cost on the U.S. health care system and insurers, particularly Medicare. The story detailed the relative harms of earlier mammograms, but did not translate those percentages into absolute numbers. For instance, women who were diagnosed with breast cancer 25 months or more after their last mammogram were “50 percent more likely” to need chemotherapy, “32 percent more likely” to need mastectomy, and “66 percent more likely” to need lymph nodes removed. However, relative risk can be misleading, sometimes inflating numbers to sound scarier than when absolute numbers are used. Also, we don’t know what kind of risk these women had at baseline, so it’s hard to know if they were higher risk. The story made no mention of the harms of earlier or more frequent screening, which have been documented time and time again. More screening can mean more false positives or more finding of breast changes that lead to more testing, such as biopsies, more costs, and more worry. The story did make clear some of the weaknesses of the study: The study found an association but did not prove causality and the study population was limited to a single health care institution. The story also mentions that the findings were presented at a meeting, which means they have not undergone peer-review. The story does not directly engage in fear-mongering. However, some of the quotes advocating for earlier and more frequent screening play into a scenario that breast cancer is lurking in every woman. A discussion of what a woman’s average lifetime risk is would have been helpful. The story quotes the study author and an outside source. The story makes clear that different advisory groups have differing guidelines for what age to start getting mammograms (40 or 50 years old). It would have been nice if the story had included examples of what makes someone higher risk or not (personal cancer history, family history, history of radiation), but we think this was satisfactory. We believe that mammograms are well-known to be widely available. And the earlier and more frequent screening described here is not earlier or more frequent than what many guidelines recommend, so would not be expected to be denied by health insurers. The story makes clear the distinctive aspects of this study —using avoidance of more aggressive treatment regimens as a deciding factor, as opposed to the more extreme avoidance of cancer death. The story goes beyond what was contained in a news release on the presentation at the American Society of Breast Surgeons annual meeting. Claim: Earlier Mammograms May Mean Less Need for Aggressive Treatments
This HealthDay news story reports on findings among women diagnosed with breast cancer: those who had longer intervals between mammograms end up getting more aggressive treatments, including chemotherapy and surgery. The story would have been stronger had it described the findings using absolute rather than relative numbers. But, we were glad to see an independent source offer some reservations about the small observational study raised. A final note — the image accompanying the story was laughably unrealistic. Mammograms are the primary screening method for detecting breast cancer. However, when to start getting mammograms and how often to get screened have been subjects of controversy for the past decade. That’s because the data on how to balance risk of developing breast cancer and the risk of harms from screening (unnecessary tests and procedures) are interpreted differently by doctors and other experts. A story that adds new data to the field and that might tip current guidelines one way or the other is newsworthy.

Paragraph: The two Massachusetts Democrats this week sent a letter to the National Institute of Allergy and Infectious Diseases within the National Institutes of Health seeking the current state of federal research into EEE and whether research into other viruses could help lead to better treatment for the mosquito-borne infection. Two new human cases of EEE were confirmed in Massachusetts this week, bringing the total this season to seven. One of the previously announced cases was fatal. There are now 36 communities statewide at critical risk, 42 at high risk, and 115 at moderate risk. Massachusetts has seen a disproportionately high number of EEE cases since 2009, second only to Florida. Claim: Sens. Markey, Warren press health officials on EEE research.
U.S. Sens. Edward Markey and Elizabeth Warren are pressing federal health officials on research efforts to combat eastern equine encephalitis.

Paragraph: The story does not discuss the costs or potential savings associated with the use of this drug. On the cost side, there are the direct costs of the drug itself as well as the diagnostic testing which must be conducted prior to administering the drug. In addition, hospitals incur significant costs to become certified as a primary stroke treatment centers, which is where candidates for tPA therapy are most likely to be taken by ambulance teams. On the savings side, successful treatment with tPA would potentially prevent significant expenditures on the care of disabled stroke patients. The story doesn’t do a good enough job explaining what they observed in the study or the benfits of tPA in general. In discussing the differences between weekday and weekend treatment, the story reports that there was a 20% difference in the likelihood of receiving tPA. In absolute terms, however, the difference between weekdays and weekends is very small (1.1% vs 0.9%). In addition, there is some discussion about why the study did not detect a reduction in deaths among patients treated on the weekend and who were more likely to receive tPA. The study could have noted that tPA has never been shown to reduce mortality in randomized clinical trials. The primary benefit of tPA—which is never explained in the story—is that it may increase the likelihood of a patient’s recovery from stroke without disability. The story was primarily about weekday vs. weekend use of tPA. While it could have mentioned other stroke treatments with proven benefits, such as aspirin, it would probably be unfair to dock points for not including this information. The story explains that the tPA is only used within 3 hours of the onset of stroke symptoms. It also hints at the fact that tPA is effective only for ischemic strokes, and that treatment is more likely to be available at certified stroke treatment centers. While it could have done more to make the limitations on tPA’s use explicit, the reader will probably come away with the sense that tPA is available only for certain patients where it can be used early. This is a satisfactory outcome. Claim: More Aggressive Treatment for Weekend Stroke

This story about the clot-dissolving drug tPA emphasized the importance of getting to the hospital quickly in cases of suspected stroke. However, it didn’t add much to a press release issued by the AMA, and in some ways was less informative. The story provided no detail on costs or potential harms of tPA treatment, and didn’t do a very good job of explaining the benefits we can expect from the drug. It buried an important finding about mortality rates far down in the story, whereas the press release from the AMA included it in the second sentence. Treatment with tPA can increase the likelihood of a full recovery from stroke if administered early enough. So if patients are more likely to receive tPA on the weekends than during the week, this is a potentially important finding that deserves to be explored. That being said, coverage of tPA needs to provide context regarding the significant risks and costs associated with this treatment.